WhatsApp
backNews Article

Gufic Biosciences Reports Rs. 6,165.45 Lakh Profit Before Tax for H1 FY2026-27, Appoints Dr. Reeta Shah as Independent Director

Company posts Rs. 6,165.45 lakh profit before tax for half year ended September 30, 2026, and names Dr. Reeta Shah as Additional Independent Director effective December 1, 2026, subject to shareholder approval

Gufic Biosciences Limited announced unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, reporting a profit before tax of Rs. 6,165.45 lakh for the half year. The company also approved the appointment of Dr. Reeta Shah as an Additional Non-Executive Independent Director for a 5-year term starting December 1, 2026, subject to shareholder approval.

1 day ago|GUFICBIO+0.00%
Gufic Biosciences LimitedGUFICBIOFinancial Results

Gufic Biosciences Limited

Financial Results

Gufic Biosciences Limited declared unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, posting a profit before tax of Rs. 6,165.45 lakh for the half year period. The company's Board of Directors also approved the appointment of Dr. Reeta Shah as an Additional Non-Executive Independent Director for five years, starting December 1, 2026, pending shareholder approval.

For the half year ended September 30, 2026, Gufic Biosciences recorded standalone revenue from operations of Rs. 54,921.95 lakh and consolidated revenue of Rs. 54,909.10 lakh.

The standalone profit before tax for the half year stood at Rs. 6,165.45 lakh, while consolidated profit before tax was Rs. 6,148.68 lakh.

Net profit for the half year was Rs. 4,594.91 lakh on a standalone basis and Rs. 4,578.17 lakh consolidated.

The Board approved the appointment of Dr. Reeta Shah as an Additional Non-Executive Independent Director for a term of five consecutive years starting December 1, 2026, subject to shareholder approval.

The Board meeting was held on November 14, 2026, starting at 5:00 p.m. and concluding at 6:35 p.m.

Highlights

  • Unaudited standalone and consolidated financial results approved for quarter and half year ended September 30, 2026.
  • Standalone revenue from operations for H1 2026: Rs. 54,921.95 lakh; consolidated: Rs. 54,909.10 lakh.
  • Profit before tax for H1 2026: Rs. 6,165.45 lakh (standalone), Rs. 6,148.68 lakh (consolidated).
  • Net profit for H1 2026: Rs. 4,594.91 lakh (standalone), Rs. 4,578.17 lakh (consolidated).
  • Appointment of Dr. Reeta Shah as Additional Non-Executive Independent Director for five years from December 1, 2026, subject to shareholder approval.
  • Dr. Reeta Shah is not debarred from holding office by SEBI or any authority.

Key Data Snapshot

Quarter ended30-Sep-26
Half Year ended30-Sep-26
Standalone Revenue from operationsRs. 54,921.95 lakh
Consolidated Revenue from operationsRs. 54,909.10 lakh
Standalone Profit Before TaxRs. 6,165.45 lakh
Consolidated Profit Before TaxRs. 6,148.68 lakh
Standalone Net ProfitRs. 4,594.91 lakh
Consolidated Net ProfitRs. 4,578.17 lakh
Appointment of Additional DirectorDr. Reeta Shah
Director term5 years from December 1, 2026
Board meeting date and timeNovember 14, 2026, 5:00 p.m. to 6:35 p.m.

What happened

  • Gufic Biosciences released unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026.
  • The company recorded a profit before tax of Rs. 6,165.45 lakh for the half year on a standalone basis.
  • The Board approved the appointment of Dr. Reeta Shah as an Additional Non-Executive Independent Director for a period of five years starting December 1, 2026, subject to shareholder approval.

Key details

  • Standalone revenue from operations for H1 2026 was Rs. 54,921.95 lakh, while consolidated revenue was Rs. 54,909.10 lakh.
  • Net profit for the half year was Rs. 4,594.91 lakh standalone and Rs. 4,578.17 lakh consolidated.
  • Dr. Reeta Shah is not barred by SEBI or any authority from holding the office of director.
  • The Board meeting was held on November 14, 2026, and lasted from 5:00 p.m. to 6:35 p.m.

Regulatory and governance context

  • The financial results were prepared under Regulation 33 of SEBI Listing Regulations and duly reviewed by a limited review report.
  • Appointment of Dr. Reeta Shah aligns with provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
  • Shareholder approval is required for the appointment of Dr. Reeta Shah as an independent director.

More News on Financial Results

View all

Latest corporate announcements and market updates in Financial Results.

View all news
Gufic Biosciences Reports Rs. 6,165.45 Lakh Profit | Stockk News